MCN1, clone 11, CAVC, clone 11
The cell line is not validated yet.
JHUi011-A
General
iPSC Line |
|
| hPSCreg name | JHUi011-A |
| Cite as: | JHUi011-A |
| Alternative name(s) |
MCN1, clone 11, CAVC, clone 11
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 1st July 2026 |
| Notes | Cell Line produced with Prof. Chulan Kwon and Prof. Kenneth Boheler, JHU |
| User feedback | |
Provider |
|
| Generator |
Johns Hopkins University (JHU)
Contact:
School of Medicine |
| Owner | School of Medicine |
| Distributors | |
| Derivation country | United States |
External iPSC Databases |
|
| BioSamples | SAMEA122914861 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | neonate |
| Ethnicity | Not available |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
| Family history | unknown |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA122914863 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | No |
| Does consent expressly permit collection of genetic information? | No |
| Does consent expressly permit storage of genetic information? | No |
| Does consent prevent dissemination of genetic information? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Johns Hopkins University, Institutional Review Board |
| Approval number | IRB00279634 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Johns Hopkins University, Institutional Review Board |
| Approval number | Congenital Heart Disease Biorepository, IRB00279634 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | ThermoFisher |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
iPSC Derivation
General |
|
| Source cell type |
Any skin fibroblast that is part of some dermis.
|
| Source cell origin |
Subdivision of trunk proper, which is demarcated from the neck by the plane of the superior thoracic aperture and from the abdomen internally by the inferior surface of the diaphragm and externally by the costal margin and associated with the thoracic vertebral column and ribcage and from the back of the thorax by the external surface of the posterolateral part of the rib cage, the anterior surface of the thoracic vertebral column and the posterior axillary lines; together with the abdomen and the perineum, it constitutes the trunk proper[FMA].
Synonyms
|
| Age of donor (at collection) | neonate |
| Collected in | 2022 |
| Passage number reprogrammed | 3 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
Immunostaining, RT-PCR
|
| Notes on reprogramming vector detection | Putative hiPSC line passaged until Sendai Virus was no longer detected (after p27) |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Initial Clones were selected and individually expanded based on the morphological appearance of the early clones (high nuclear to cytosolic ratio, tight/compact morphologies) |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method | Initially, with accutase and subsequently with TrypLE or EDTA |
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | Yes |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| NANOG |
Yes |
Morphology pictures
Brightfield images of p4 clones
Self-renewal
Positive
Endoderm
Positive
Mesoderm
Positive
Ectoderm score
Positive
Data analysis report
Scorecard
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
47,XX containing a Gain on Chromosome 21
Passage number: p39
Karyotyping method:
KaryoStat by ThermoFisher
|
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.